// App-Quantinova.ai

354 : Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Researchers

Presenter

  • Barry Storer

Principal Investigators

  • Benedetto Bruno

  • Parameswaran Hari

  • Thomas Chauncey

  • Yoshihiro Inamoto

  • Paul J. Martin

  • Rainer Storb

  • David G. Maloney

  • Brenda M. Sandmaier

  • Mary E.D. Flowers

Medical Centers

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

Locations

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Hematological malignancies

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Hodgkin's Lymphoma

  • Multiple Myeloma

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 2AP

  • Hematocrit

  • Tenascin-C

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved